## OP IRINOTECAN / CETUXIMAB / VEMURAFENIB (EVERY 14 DAYS)

Types: ONCOLOGY TREATMENT

Synonyms: BRAF, V600E, IRINOTECAN, IRIN, CAMPTOSAR, CAMP, CET, CETUXIMAB, VEMURAFENIB,

ZELBORAF, COLORECTAL, VIC

**Take-Home Medications** Repeat 1 time Cycle length: 1 day

Day 1 Perform every 1 day x1

**Provider Communication** 

ONC PROVIDER COMMUNICATION
Interval: -- Occurrences: --

Comments: Presence of V600 mutation of BRAF gene must be documented by a

CLIA-approved laboratory prior to initiation of Vemurafenib therapy.

Take-Home Medications Prior to Treatment

vemurafenib (ZELBORAF) 240 mg tablet tablet

Dose: 960 mg Route: oral 2 times daily

Dispense: 224 tablet Refills: 2 Start: S End: S+14

Instructions:

Take 4 tablets (total 960 mg) by mouth twice

daily on days 1 to 14.

Cycles 1 to 6 Repeat 6 times Cycle length: 14 days

Day 1 Perform every 1 day x1

Appointment Requests

INFUSION APPOINTMENT REQUEST
Interval: -- Occurrences: --

Labs

☑ COMPREHENSIVE METABOLIC PANEL

Interval: -- Occurrences: --

☑ CBC WITH PLATELET AND DIFFERENTIAL

Interval: -- Occurrences: --

**☑ MAGNESIUM LEVEL** 

Interval: -- Occurrences: --

**Nursing Orders** 

ONC VERIFY PATIENT TAKING HOME MEDS

Interval: -- Occurrences: --

Comments: Verify that patient is taking home meds as directed.

Outpatient Electrolyte Replacement Protocol

**TREATMENT CONDITIONS 39** 

Interval: -- Occurrences: --

Comments: Potassium (Normal range 3.5 to 5.0mEq/L)

o Protocol applies for SCr less than 1.5. Otherwise, contact

MD/NP

Protocol applies only to same day lab value.

o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or

PO and contact MD/NP

o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO Serum potassium 3.5 mEq/L or greater, do not give potassium

replacement

o If patient meets criteria, order SmartSet called "Outpatient

Electrolyte Replacement"

o Sign electrolyte replacement order as Per protocol: cosign

required

#### **TREATMENT CONDITIONS 40**

Interval: -- Occurrences: --

Comments: Magnesium (Normal range 1.6 to 2.6mEq/L)

o Protocol applies for SCr less than 1.5. Otherwise, contact

MD/NP

o Protocol applies only to same day lab value.

o Serum Magnesium less than 1.0mEq/L, give 2 gram magnesium

sulfate IV and contact MD/NP

o Serum Magnesium 1.0 to 1.2mEq/L, give 2 gram magnesium

sulfate IV

o Serum Magnesium 1.3 to 1.5mEq/L, give 1 gram magnesium

sulfate IV

Serum Magnesium 1.6 mEq/L or greater, do not give

magnesium replacement

o If patient meets criteria, order SmartSet called "Outpatient

Electrolyte Replacement"

o Sign electrolyte replacement order as Per protocol: cosign

required

#### **Provider Communication**

#### **ONC PROVIDER COMMUNICATION 2**

Interval: -- Occurrences: --

Comments: Tumor KRAS gene status should be determined prior to initiation of

therapy. KRAS type: Please Push F2:115540219.

#### **Nursing Orders**

#### **TREATMENT CONDITIONS 4**

Interval: -- Occurrences: --

Comments: HOLD and notify provider if ANC LESS than 1000; Platelets LESS than

100,000; Total Bilirubin GREATER than 1.5; ALT/AST GREATER than 3

times upper normal limit; or Serum Creatinine GREATER than 1.2

#### Line Flush

sodium chloride 0.9 % flush 20 mL

Dose: 20 mL Route: intravenous PRN

Start: S

#### Nursing Orders

#### sodium chloride 0.9 % infusion 250 mL

Dose: 250 mL Route: intravenous once @ 30 mL/hr for 1 dose

Start: S Instructions:

To keep vein open.

#### **Pre-Medications**

## ondansetron (ZOFRAN) 16 mg, dexamethasone

### ☑ (DECADRON) 12 mg in sodium chloride 0.9%

50 mL IVPB

Dose: -- Route: intravenous once over 15 Minutes for 1 dose

Start: S End: S 11:30 AM

Ingredients: Name Type Dose Selected Adds Vol.

ONDANSETRON Medications 16 mg Yes No

HCL (PF) 4 MG/2 ML INJECTION SOLUTION

DEXAMETHASONE Medications 12 mg Yes No

4 MG/ML

		INJECTION SOLUTION SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS SOLUTION	Base Base	50 mL	Always No	Yes Yes	
	☐ ondansetron (ZOFRAN)						
	Dose: 16 mg Start: S	Route: oral End: S 11:30 AM	once for 1 dos	se			
	☐ dexamethasone (DECA						
	Dose: 12 mg Start: S	once for 1 dos	1 dose				
	□ palonosetron (ALOXI) injection 0.25 mg						
	Dose: 250 mcg Start: S Instructions: For OUTPATIENT use	Route: intravenous End: S 3:00 PM	once for 1 dose				
	aprepitant (CINVANTI) (NON-PVC) 5% 130 mL Dose: 130 mg Start: S	once over 30 Minutes for 1 dose					
	Ingredients:	Name APREPITANT 7.2 MG/ML INTRAVENOUS EMULSION	<b>Type</b> Medications	<b>Dose</b> 130 mg		Adds Vol. Yes	
		DEXTROSE 5 % IN WATER (D5W) IV SOLP (EXCEL; NON-PVC)	Base	130 mL	Yes	Yes	
		SODIUM CHLORIDE 0.9 % IV SOLP (EXCEL;NON-PVC)	Base	130 mL	No	Yes	
Pre-M	Pre-Medications						
	atropine injection 0.25 Dose: 0.25 mg Start: S	mg Route: intravenous	once PRN				
Pre-M	Medications						
	diphenhydrAMINE (BE mg	NADRYL) injection 25					
	Dose: 25 mg Start: S Instructions:	Route: intravenous	once for 1 dos	se			
Chem	Give 30 minutes prior to cetuximab.  hemotherapy						
J J	cetuximab (ERBITUX) Dose: 500 mg/m2	500 mg/m2 in 0 mL Route: intravenous	once over 120		or 1 dose		
	Offset: 30 Minutes Instructions: Administer with low protein binding 0.22 micron filter. Do not shake. Do not mix with other medications. Flush IV line with NS at the end						

of infusion.

1st infusion: Infuse first 10 mL over 10 minutes and observe patient for 30 minutes for allergic reactions if infusion tolerated, infuse loading dose over 120 minutes.

Rate of infusion not to exceed 10 mg/minute (5

mL/minute)

Ingredients: Name Dose Selected Adds Vol. Type

**CETUXIMAB 100** Medications 500 Main Yes MG/50 ML Ingredient mg/m2

**INTRAVENOUS** SOLUTION

Chemotherapy

irinotecan (CAMPTOSAR) 180 mg/m2 in dextrose 5% 500 mL chemo IVPB

Dose: 180 mg/m2 Route: intravenous once over 90 Minutes for 1 dose

Offset: 2.5 Hours

Instructions:

Protect from light

Ingredients: Type Selected Adds Vol. Name Dose

IRINOTECAN 100 Main Medications 180 Yes MG/5 ML mg/m2 Ingredient

**INTRAVENOUS** SOLUTION

DEXTROSE 5 % IN QS Base 500 mL Yes Yes

WATER (D5W) **INTRAVENOUS** SOLUTION

SODIUM QS Base 500 mL No Yes

CHLORIDE 0.9 % **INTRAVENOUS** SOLUTION

Hematology & Oncology Hypersensitivity Reaction Standing Order

#### **ONC NURSING COMMUNICATION 82**

Interval: --Occurrences: --

Comments: Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms

only – itching, flushing, periorbital edema, rash, or runny nose)

1. Stop the infusion.

2. Place the patient on continuous monitoring.

3. Obtain vital signs.

4. Administer Normal Saline at 50 mL per hour using a new bag and new

intravenous tubing.

5. If greater than or equal to 30 minutes since the last dose of

Diphenhydramine, administer Diphenhydramine 25 mg intravenous

6. If less than 30 minutes since the last dose of Diphenhydramine,

administer Fexofenadine 180 mg orally and Famotidine 20 mg

intravenous once.

7. Notify the treating physician.

8. If no improvement after 15 minutes, advance level of care to Grade 2

(Moderate) or Grade 3 (Severe).

9. Assess vital signs every 15 minutes until resolution of symptoms or

otherwise ordered by covering physician.

#### **ONC NURSING COMMUNICATION 4**

Interval: --Occurrences: --

Comments: Grade 2 – MODERATE Symptoms (cardiovascular, respiratory, or

aastrointestinal symptoms - shortness of breath. wheezing. nausea.

vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)

- 1. Stop the infusion.
- 2. Notify the CERT team and treating physician immediately.
- 3. Place the patient on continuous monitoring.
- 4. Obtain vital signs.
- 5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
- 6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
- 7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Fexofenadine 180 mg orally and Famotidine 20 mg intravenous once.
- 8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
- 9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

#### **ONC NURSING COMMUNICATION 83**

Interval: --

Occurrences: --

Comments:

Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)

- 1. Stop the infusion.
- 2. Notify the CERT team and treating physician immediately.
- 3. Place the patient on continuous monitoring.
- 4. Obtain vital signs.
- 5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.

  6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to
- Administer Oxygen at 2 L per minute via nasal cannula. Hitrate t maintain O2 saturation of greater than or equal to 92%.
- 7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
- 8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
- 9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
- 10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

#### diphenhydrAMINE (BENADRYL) injection 25

mg

Dose: 25 mg Route: intravenous PRN

Start: S

fexofenadine (ALLEGRA) tablet 180 mg

Dose: 180 mg Route: oral PRN

Start: S

famotidine (PEPCID) 20 mg/2 mL injection 20

mg

Dose: 20 mg Route: intravenous PRN

Start: S

hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg

Dose: 100 mg Route: intravenous PRN

dexamethasone (DECADRON) injection 4 mg

Dose: 4 mg Route: intravenous PRN

Start: S

## epINEPHrine (ADRENALIN) 1 mg/10 mL ADULT injection syringe 0.3 mg

Dose: 0.3 mg Route: subcutaneous PRN

Start: S

#### **Nursing Orders**

#### **ONC NURSING COMMUNICATION 14**

Interval: -- Occurrences: --

Comments: Contact Provider if drug-induced acneiform rash develops and covers

more than 25 per cent of the body.

#### Discharge Nursing Orders

# ONC NURSING COMMUNICATION 76 Interval: -- Occurrences: -Comments: Discontinue IV.

#### Discharge Nursing Orders

#### 

Dose: 20 mL Route: intravenous PRN

#### ☑ HEParin, porcine (PF) injection 500 Units

Dose: 500 Units Route: intra-catheter once PRN

Start: S Instructions:

Concentration: 100 units/mL. Heparin flush for

Implanted Vascular Access Device

maintenance.